.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, people with metastatic intestinal tumors that acquired biomarker-matched therapies based upon distributing lump DNA profiling showed a greater medical benefit than those getting unrivaled treatment.